Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloxiri in Advanced Unresectable Pancreatic Adenocarcinoma
NCT01558869Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Apr 2012
- Primary completion
- Dec 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by The University of Hong Kong. Started Apr 2012; status: completed.
02
Drugs
capecitabineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01558869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558869.